Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING

Molecular Immunoassay Diagnoses Melioidosis

By Labmedica International staff writers
Posted on 18 Feb 2013
Image: Burkholderia pseudomallei (Photo courtesy US Centers of Disease Control.
Image: Burkholderia pseudomallei (Photo courtesy US Centers of Disease Control.
Melioidosis is caused by the Gram-negative bacterium Burkholderia pseudomallei for which the standard test growing it on microbiological culture media, which requires at least 3 to 4 days to obtain a result, hindering successful treatment of acute disease.

Where the seroprevalence of antibodies to B. pseudomallei is relatively low, serology is a potentially advantageous addition to culture in the diagnosis of melioidosis and serology would be very effective in diagnosing travelers and military personnel returning from endemic tropical areas.

Scientists at James Cook University (Douglas, Australia) developed an enzyme-linked immunosorbent assay (ELISA) and a quantitative immunopolymerase chain reaction (PCR) assay capable of detecting melioidosis-specific antibodies. They demonstrated their validity with indirect haemagglutination assay (IHA)-negative sera from patients with melioidosis. A total of 10 serum samples from three IHA-positive and three IHA-negative melioidosis patients were tested along with sera from six healthy controls.

To verify the assays, the scientists used various techniques including immunoblotting, indirect peroxidase-conjugated protein G ELISA, and indirect terminus utilization substance (Tus) - DNA replication terminator sites (Ter)-lock immuno-PCR. Both the latter systems Both systems were based on the detection of immunoglobulin G (IgG) by protein G conjugated to a signal generation system consisting of either the enzymatic activity of peroxidase or a quantitative PCR (qIPCR) read-out in the case of Tus and the TT-lock-T DNA probe. All patient sera, including that collected at presentation and in subsequent follow-up collections, reacted against the B. pseudomallei antigenic fraction in both the G-peroxidase ELISA and TT-lock qIPCR format. Individual negative control sera from six healthy controls did not react against the B. pseudomallei antigenic fraction in either assay.


The authors concluded that although the indirect TT-lock qIPCR system is slightly slower than the ELISA format, it requires the least amount of serum and would be advantageous when multiple testing is required for the confirmation of disease. The ability to detect antibodies in patient sera that were persistently IHA negative is very promising, indicating that both immunoassay formats will be ideal for the rapid and reliable diagnosis of melioidosis in patients in nonendemic regions. The study was published in the February 2013 edition of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

James Cook University



EUROIMMUN AG
Sekisui Diagnostics
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.